- Home
- CNC vs RPRX Comparison
CNC vs RPRX Comparison
Compare CNC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNC | RPRX |
|---|---|---|
| Founded | 1984 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 16.2B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNC | RPRX |
|---|---|---|
| Price | $40.60 | $38.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | $40.06 | ★ $45.75 |
| AVG Volume (30 Days) | ★ 7.3M | 4.0M |
| Earning Date | 02-03-2026 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.75 |
| Revenue | ★ $167,680,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $32.54 | $37.13 |
| Revenue Next Year | $0.19 | $1.48 |
| P/E Ratio | ★ N/A | $21.92 |
| Revenue Growth | ★ 14.57 | 3.70 |
| 52 Week Low | $25.08 | $24.05 |
| 52 Week High | $66.81 | $41.24 |
Technical Indicators
Market Signals| Indicator | CNC | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.87 | 48.04 |
| Support Level | $37.25 | $37.88 |
| Resistance Level | $41.74 | $38.93 |
| Average True Range (ATR) | 1.15 | 0.77 |
| MACD | 0.17 | -0.20 |
| Stochastic Oscillator | 75.72 | 25.14 |
Price Performance
Historical ComparisonAbout CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.